597 related articles for article (PubMed ID: 28244683)
1. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
2. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
4. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
5. Human polycystin-2 transgene dose-dependently rescues ADPKD phenotypes in Pkd2 mutant mice.
Li A; Tian X; Zhang X; Huang S; Ma Y; Wu D; Moeckel G; Somlo S; Wu G
Am J Pathol; 2015 Oct; 185(10):2843-60. PubMed ID: 26435415
[TBL] [Abstract][Full Text] [Related]
6. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
[TBL] [Abstract][Full Text] [Related]
7. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
8. Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice.
Park EY; Sung YH; Yang MH; Noh JY; Park SY; Lee TY; Yook YJ; Yoo KH; Roh KJ; Kim I; Hwang YH; Oh GT; Seong JK; Ahn C; Lee HW; Park JH
J Biol Chem; 2009 Mar; 284(11):7214-22. PubMed ID: 19098310
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
10. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
11. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
[TBL] [Abstract][Full Text] [Related]
12. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
13. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.
Zhu P; Sieben CJ; Xu X; Harris PC; Lin X
Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.
Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR
Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947
[TBL] [Abstract][Full Text] [Related]
15. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA
Aboudehen K; Farahani S; Kanchwala M; Chan SC; Avdulov S; Mickelson A; Lee D; Gearhart MD; Patel V; Xing C; Igarashi P
J Biol Chem; 2018 Jun; 293(24):9388-9398. PubMed ID: 29716997
[TBL] [Abstract][Full Text] [Related]
19. Pkd2 Deficiency in Embryonic Aqp2 + Progenitor Cells Is Sufficient to Cause Severe Polycystic Kidney Disease.
Tsilosani A; Gao C; Chen E; Lightle AR; Shehzad S; Sharma M; Tran PV; Bates CM; Wallace DP; Zhang W
J Am Soc Nephrol; 2024 Apr; 35(4):398-409. PubMed ID: 38254271
[TBL] [Abstract][Full Text] [Related]
20. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
